DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for papillary glioneuronal tumor — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease modulePapillary glioneuronal tumor maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for papillary glioneuronal tumor is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
fibroblast growth factor receptor 1 (FGFR1) — FGFR1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 4-methylpiperazin-1-yldrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5A46 · 2.63 Å · ligand 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one (38O). Experimental structure, not a prediction.
What the evidence adds up to
Papillary glioneuronal tumor is a rare central nervous system neoplasm classified by the WHO as grade I neuronal-glial tumour, characterised by pseudopapillary architecture and a mixed astrocytic and neuronal cell population. The histogenesis remains unclear. In one reported case of a 12-year-old boy, the tumour cells expressed PDGFRalpha, Olig2 and Nestin, which the authors interpreted as supporting an origin from common progenitor cells in the subependymal plate. Another abstract notes that Olig2 expression in a fraction of tumour cells has been reported, suggesting an oligodendroglial or oligodendroglia-like component.
The abstracts provide no data on drug treatment, response rates, survival, or any clinical outcomes. No drug is mentioned in any of the three abstracts. The 2015 report discusses clinical, neuroradiological and surgical features and compares its findings with literature, but gives no numerical results. The 2007 and 2010 abstracts are identical in content and likewise contain no treatment information.
What is missing is any clinical trial testing a drug in papillary glioneuronal tumor, any evidence of drug activity, and any patient stratification beyond histology. No funding for drug-repurposing research in this tumour type is described. Without such data, no conclusion about drug efficacy can be drawn.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Neuropathology · 2007 · 41 citations
Papillary glioneuronal tumor
AbstractPapillary glioneuronal tumor (PGNT) is a rare, recently recognized tumor type histologically characterized by pseudopapillary architecture associated with compact areas composed of neuronal elements in different maturation states. The histogenesis of this tumor type is still unclear. The immunophenotype of PGNT comprises expression of several glial and neuronal proteins. Recently, immunohistochemical expression of Olig2 in a fraction of tumor cells has been reported, suggesting an additional oligodendroglial or at least oligodendroglia-like tumor cell component. We report a further case of papillary glioneuronal tumor in a 12-year-old boy with immunohistochemical expression of PDGFRalpha, Olig2 and Nestin in support of a postulated origin of this tumor type from common progenitor cells in the subependymal plate. Nevertheless, further studies are needed to clarify the histogenesis of PGNT.
Il Giornale di Chirurgia - Journal of the Italian Association of Hospital Surgeons · 2015 · 21 citations · open access
Papillary glioneuronal tumor: case report and review of literature
AbstractPapillary glioneuronal tumor (PGNT) is a recently described central nervous system neoplasm that mostly occurs in the supratentorial system, adjacent to the lateral ventricles. In 2007, WHO classified PGNT as grade I neuronal-glial tumor because of the characteristic papillary architecture and bipartite (astrocytic and neuronal/neurocytic) cell population. As a newly established entity of mixed glioneuronal tumor family, PGNT attracted extensive attention recently. In our report we discuss the clinical, neuroradiological and surgical features. The final result is compared with literature data.
Náutica: revista mensual de náutica deportiva y de recreo, vela y motor · 2010 · 0 citations
Neumáticas y semirrígidas: ¿quién dijo crisis?
AbstractPapillary glioneuronal tumor (PGNT) is a rare, recently recognized tumor type histologically characterized by pseudopapillary architecture associated with compact areas composed of neuronal elements in different maturation states. The histogenesis of this tumor type is still unclear. The immunophenotype of PGNT comprises expression of several glial and neuronal proteins. Recently, immunohistochemical expression of Olig2 in a fraction of tumor cells has been reported, suggesting an additional oligodendroglial or at least oligodendroglia-like tumor cell component. We report a further case of papillary glioneuronal tumor in a 12-year-old boy with immunohistochemical expression of PDGFRalpha, Olig2 and Nestin in support of a postulated origin of this tumor type from common progenitor cells in the subependymal plate. Nevertheless, further studies are needed to clarify the histogenesis of PGNT.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
